Fellowship Position, Early Clinical Drug Development

Publication date: 19 November 2018

Institution

Vall d'Hebron Institute of Oncology 
Centro Cellex, Calle Natzaret, 115-117
08035 Barcelona 
Spain

VHIO’s translation toward precision oncology: www.vhio.net

The Vall d´Hebron University Hospital (HUVH) is one of the largest hospitals in Spain. Our Medical Oncology Department, directed by Josep Tabernero, provides excellent patient care and is involved in both basic and clinical research, with a clear focus on translational oncology. The interaction between clinical research and laboratory investigation is paramount since it spurs the development of research opportunities.
At our Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa”, we perform early clinical studies (phase I trials) with novel therapeutics. The main focus is translating experimental targeted treatment strategies to the clinical level for testing. Our main areas of interest include first-in-human trials, novel combinations of targeted therapies and biomarker-driven studies. Historically, the phase I Unit has steadily grow in breadth, scope and recognition, and has since become one of the largest in Europe both in terms of dedicated space, as well as number of trials and patients enrolled.

Facilties

UITM is a dedicated unit for Phase I trials located within the Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Faithful to VHIO’s purely translational and multidisciplinary research model, collaboration and connectivity between and among our various tumor-specific units (Breast cancer, GI cancers, etc.), translational research groups and core technologies including molecular oncology, is essential.
In addition to our expertise in early drug development and clinical trial design, we are also involved in biomarker development (CTC, Pharmacodynamics, etc.), patient-derived xenografts, and the molecular analysis of tumors for treatment selection. We have the necessary state of-the-art facilities for translational research of excellence, with other VHIO groups focusing on important areas including cancer stem cells, cell-signaling, resistance to targeted therapies, cancer genomics, and molecular oncology.

About VHIO

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2006, has established itself as a comprehensive cancer center of proven excellence internationally. It is thanks to Josep Tabernero’s directorship and VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.

Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.

VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types

Job

Job Title

Fellowship Position, Early Clinical Drug Development 

Job Description

We seek one or two fellows interested in working in clinical and translational research within our Phase I program. The successful candidate will be in charge of patients and clinical trials of our Early Clinical Drug Development Group. The appointed individual will be mentored by one of our Senior Consultants and will be involved in clinical trials, molecular prescreening, and translational projects of our Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa”.
Development of Investigator Initiated Trials and projects will be highly encouraged, as well as involvement in collaborative research with other VHIO groups.
The duration of the Fellowship will be between 1 - 2 years depending on previous experience and the contract may be extended at a later date based on professional merit. Review of applications will commence immediately and we hope to incorporate the fellow no later than January 2019.

Number of vacancies: 1-2

Requirements

The appointed fellow will be board certified a medical oncology. The main focus of VHIO’s UITM is developing targeted therapies against cancer which should also be of special interest to the fellow. Prior experience in clinical research will be favorably considered. Since the fellow will be involved with patients treated in Phase I trials, excellent communication skills in Spanish are imperative. Good written and spoken English are required for communication with sponsor and
other investigators.

How to apply

Please send a CV and cover letter to: selecciorrhh@vhio.net, including the reference “23/2018” in the subject line of your email.

Application deadline

Deadline for application is 31 December 2018.

ESMO Disclaimer

It is the Advertisers' responsibility to ensure that any material submitted for inclusion on this section of the ESMO website complies with all relevant laws and regulations (including the Data Protection Act 1998).

Individuals applying for the position above should make direct contact with the institution making the offer and are responsible to verify the validity of the offer. The European Society for Medical Oncology will not accept responsibility for any error, omission or inaccuracy in any job advertising materials on this section of the website.

Submissions from individuals seeking jobs/positions will not be accepted.

Job openings at the European Society for Medical Oncology’s headquarters are available on  ESMO is Hiring page and on  LinkedIn.